Skip to main content

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040)

A randomised, open-label, phase 3 study

11 January 2019 (Last updated: 11 Jan 2019 09:09)

There is an interesting report of this randomised, open-label, phase 3 study at 97 medical centres in 20 countries in The Lancet

There are few effective treatment options for patients with recurrent or metastatic head-and-neck squamous cell carcinoma. Pembrolizumab showed antitumour activity and manageable toxicity in early-phase trials. We aimed to compare the efficacy and safety of pembrolizumab versus standard-of-care therapy for the treatment of head-and-neck squamous cell carcinoma.

This article may be accessed via the Lancet website